Lv1
10 积分 2025-11-18 加入
A PD-L1xCD3 bispecific nanobody as a novel T-cell engager in treating PD-L1 overexpression melanoma
3个月前
已完结
Bispecific and multispecific antibodies in oncology: opportunities and challenges
5个月前
已完结
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
5个月前
已完结
CD28 co-stimulation: novel insights and applications in cancer immunotherapy
7个月前
已完结
皖公网安备34019202002308
